SALL2 and breast carcinoma: Our findings shed light on the role of SALL2 in the transcriptional regulation of ER, and present a potential clinical biosignature that could be used for subgrouping breast cancer patients and identify those who might benefit from co‐therapy with tamoxifen and DNMT inhibitor.